Abdulrahman Katib on RENOVE’s Support of Practice in VTE Longterm Managment
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
”RENOVE is an important RCT that supported our practice in VTE longterm managment.
It was a high-quality multicenter randomized clinical trial that provided strong real-world evidence on extended anticoagulation after VTE.
It showed that long-term dosing decisions should focus not only on preventing recurrence, but also on reducing bleeding risk, which directly improved how we individualize therapy in practice.
Since RENOVE, our approach became more patient-centered, with more confident use of reduced-dose DOAC strategies in selected patients needing extended anticoagulation.”
Read the full article here.
Article: Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial
Authors: Francis Couturaud et al. for the RENOVE Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 22, 2026, 18:11Bharath Kumar V.։ Advancing Safer Anticoagulation for Cancer-Associated Thrombosis
-
Sep 22, 2026, 18:10Fatima Zahra: ASH Released New Guidelines on the Diagnosis of Iron Deficiency
-
Sep 22, 2026, 17:49Nirav Dhanesha: Targeting FXI for Safer Anticoagulation
-
Sep 22, 2026, 17:17Eric Lambert: Intravascular Imaging and the Future of Precision PCI
-
Sep 22, 2026, 16:45Claudiu Stoicescu: Are We Starting Cardiovascular Risk Assessment Too Late?
-
Sep 22, 2026, 16:35Complement – Coagulation Crosstalk in Thrombosis
-
Sep 22, 2026, 16:20Ila Bappa Ibrahim: Bringing Sickle Cell Innovation Closer to Communities
-
Sep 22, 2026, 16:02Ana Pedrero Gil: Peri-operative Management of Patients Undergoing Day Surgery
-
Sep 22, 2026, 15:27Zia Ullah: RBC-Derived Extracellular Vesicles as Potential Biomarkers of Thrombotic Risk in Dengue